ER
FOLD

Enlightenment Research’s Amicus Therapeutics FOLD Stock Holding History

Enlightenment Research’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-12,000
Closed -$115K – 134
2020
Q1 		$115K Buy
+12,000
New +$114K 0.12% 154

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Enlightenment Research's FOLD Position: Q2 2020 in Review

Enlightenment Research sold out of Amicus Therapeutics (FOLD) in Q2 2020, closing a stake of 12,000 shares — an estimated $115K sold.

Enlightenment Research first reported a position in FOLD in Q1 2020 and held it in 1 quarter. The position peaked at $115K in Q1 2020. 227 funds tracked by Wall St. Rank hold FOLD as of Q2 2020.

  • Enlightenment Research reported no remaining Amicus Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Enlightenment Research sold 12,000 Amicus Therapeutics shares in Q2 2020, an estimated $115K.
  • Enlightenment Research first reported a position in Amicus Therapeutics in Q1 2020 and held it in 1 quarter.
  • Enlightenment Research's Amicus Therapeutics position peaked at $115K in Q1 2020.
  • 227 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2020.

Based on Enlightenment Research's 13F filing for Q2 2020, filed 6 Aug 2020.